Cefotetan - Injection products
Additional FDA-identified interpretive criteria
| Minimum Inhibitory Concentrations (mcg/mL) |
Disk Diffusion (zone diameter in mm) |
|||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Haemophilus influenzae | ≤4 | 8 | ≥16 | - | - | - |
S = Susceptible; I = Intermediate; R = Resistant
Susceptibility interpretive criteria for microorganisms are based on a dosing regimen of 2 grams every 12 hours.
Exceptions to the recognized standard of CLSI M100
| Minimum Inhibitory Concentrations (mcg/mL) |
Disk Diffusion (zone diameter in mm) |
|||||
|---|---|---|---|---|---|---|
| Pathogen | S | I | R | S | I | R |
| Enterobacterales | ≤4 | 8 | ≥16 | - | - | - |
| Anaerobes | ≤4 | 8 | ≥16 | - | - | - |
| Neisseria gonorrhoeae | ≤4 | 8 | ≥16 | - | - | - |
S = Susceptible; I = Intermediate; R = Resistant
Susceptibility interpretive criteria for microorganisms are based on a dosing regimen of 2 grams every 12 hours